Rosavin Ameliorates Hepatic Inflammation and Fibrosis in the NASH Rat Model via Targeting Hepatic Cell Death
Authors:
- Reda AlbadawyRAReda Albadawy
- Amany Helmy HasaninAHAmany Helmy Hasanin
- Sara H. A. AgwaSASara H. A. Agwa
- Shaimaa HamadySHShaimaa Hamady
- Yasmin M. Aboul-ElaYAYasmin M. Aboul-Ela
- Mona Hussien RaafatMRMona Hussien Raafat
- Samaa Samir KamarSKSamaa Samir Kamar
- Mohamed OthmanMohamed Othman
- Yahia A. YahiaYYYahia A. Yahia
- Marwa MatboliMMMarwa Matboli
Open Access
- 5 September 2022
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (17) , 10148
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) represents the most common form of chronic liver disease that urgently needs effective therapy. Rosavin, a major constituent of the Rhodiola Rosea plant of the family Crassulaceae, is believed to exhibit multiple pharmacological effects on diverse diseases. However, its effect on non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, and the underlying mechanisms are not fully illustrated. Aim: Investigate the pharmacological activity and potential mechanism of rosavin treatment on NASH management via targeting hepatic cell death-related (HSPD1/TNF/MMP14/ITGB1) mRNAs and their upstream noncoding RNA regulators (miRNA-6881-5P and lnc-SPARCL1-1:2) in NASH rats. Results: High sucrose high fat (HSHF) diet-induced NASH rats were treated with different concentrations of rosavin (10, 20, and 30 mg/kg/day) for the last four weeks of dietary manipulation. The data revealed that rosavin had the ability to modulate the expression of the hepatic cell death-related RNA panel through the upregulation of both (HSPD1/TNF/MMP14/ITGB1) mRNAs and their epigenetic regulators (miRNA-6881-5P and lnc-SPARCL1-1:2). Moreover, rosavin ameliorated the deterioration in both liver functions and lipid profile, and thereby improved the hepatic inflammation, fibrosis, and apoptosis, as evidenced by the decreased protein levels of IL6, TNF-α, and caspase-3 in liver sections of treated animals compared to the untreated NASH rats. Conclusion: Rosavin has demonstrated a potential ability to attenuate disease progression and inhibit hepatic cell death in the NASH animal model. The produced effect was correlated with upregulation of the hepatic cell death-related (HSPD1, TNF, MMP14, and ITGB1) mRNAs—(miRNA-6881-5P—(lnc-SPARCL1-1:2) RNA panel.Keywords
Funding Information
- Academy of Science and Technology (ASRT) (jesor_5269)
This publication has 64 references indexed in Scilit:
- High-Throughput parallel blind Virtual Screening using BINDSURFBMC Bioinformatics, 2012
- Discovery of hundreds of mirtrons in mouse and human small RNA dataGenome Research, 2012
- Automated 3D structure composition for large RNAsNucleic Acids Research, 2012
- Crystal structure of α5β1 integrin ectodomain: Atomic details of the fibronectin receptorJournal of Cell Biology, 2012
- ViennaRNA Package 2.0Algorithms for Molecular Biology, 2011
- The Dimer Interface of the Membrane Type 1 Matrix Metalloproteinase Hemopexin DomainJournal of Biological Chemistry, 2011
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005
- Gene Expression Omnibus: NCBI gene expression and hybridization array data repositoryNucleic Acids Research, 2002
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001